Get 40% Off
🤯 This Tech Portfolio is up 29% YTD! Join Now to Get April’s Top PicksGet The Picks – Just 99 USD

Novavax's Covid-19 Vaccine Approval in the U.S. Could Be Delayed - CNBC

Published 06/09/2022, 06:16 AM
Updated 06/09/2022, 10:29 AM
© Reuters Novavax's (NVAX) Covid-19 Vaccine Approval in the U.S. Could Be Delayed - CNBC

© Reuters Novavax's (NVAX) Covid-19 Vaccine Approval in the U.S. Could Be Delayed - CNBC

By Sam Boughedda

The U.S. Food and Drug Administration's (FDA) decision on Novavax 's (NASDAQ:NVAX) Covid-19 vaccine could be delayed, according to a report by CNBC.

An FDA spokesperson told CNBC that the regulatory body will have to review modifications to the drugmaker's manufacturing process before it is able to authorize the Covid-19 vaccine in the U.S.

On Tuesday, an FDA committee of independent vaccine experts voted to recommend the Novavax vaccine for use in the U.S. following a review of safety and efficacy data.

Novavax's vaccine is already approved in Europe and the UK.

The FDA has previously authorized other vaccines fairly rapidly, however, Novavax's vaccine could take longer for approval. The FDA reportedly told CNBC that Novavax informed them of manufacturing process changes on June 3, only a few days before reviewing its vaccine’s safety and effectiveness.

The FDA spokesperson quoted CNBC as saying it will "carefully review this and any additional information submitted by the firm."

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.